Skip to main content

Posts

  • The First Modified Delphi Consensus Statement for Resuming Bariatric and Metabolic Surgery in the COVID-19 Times

    2 Aug, 2020
    An article talking about Bariatric and Metabolic Surgery during COVID-19 pandemic. 
    The purpose of this study was to achieve consensus amongst a global panel of expert bariatric surgeons on various aspects of resuming Bariatric and Metabolic Surgery (BMS) during the Coronavirus Disease-2019 (COVID-19) pandemic. A modified Delphi consensus-building protocol was used to build consensus amongst 44 globally recognised bariatric surgeons. The experts were asked to either agree or disagree ...
  • Coronavirus vaccine tracker: how close are we to a vaccine?

    30 Jul, 2020
    More than 140 teams of researchers are racing to develop a safe and effective coronavirus vaccine.

    Researchers around the world are racing to develop a vaccine against Covid-19, with more than 140 candidate vaccines now tracked by the World Health Organization (WHO).

    Vaccines normally require years of testing and additional time to produce at scale, but scientists are hoping to develop a coronavirus vaccine within 12 to 18 months.

    Vaccines mimic the...
  • COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives

    30 Jul, 2020
    Nature publishes an article talking about COVID-19 and cardiovascular disease.
    Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic that has affected the lives of billions of individuals. Extensive studies have revealed that SARS-CoV-2 shares many biological features with SARS-CoV, the zoonotic virus that caused the 2002 outbreak of severe acute respiratory syndrome, includ...
  • Managing COVID-19 in Surgical Systems

    30 Jul, 2020


    Managing COVID-19 in Surgical Systems

    Annals of Surgery published this paper about surgical systems.As COVID-19 spreads quickly from Europe and Asia to the rest of the world, hospitals are rapidly becoming hot zones for treatment and transmission of this disease in settings with rising community transmission. Health care workers are increasingly contracting this illness, decreasing the human resources available to care for a population in crisis.
    For furt...
  • Investigadores españoles del Grupo de Análisis Científico sobre Coronavirus del ISCIII

    29 Jul, 2020


    Edición genética con CRISPR y estudios de serovigilancia, nuevos informes del Grupo ISCIII de Análisis sobre Coronavirus


    El Grupo de Análisis Científico sobre Coronavirus del ISCIII ha publicado dos nuevos informes, sobre los posibles usos de la tecnología CRISPR de edición genética y sobre el desarrollo de estudios de serovigilancia epidemiológica, que como en casos anteriores incluyen un resumen divulgativo y un texto completo de carác...
  • Coronavirus: Protein treatment trial 'a breakthrough'

    28 Jul, 2020

    The preliminary results of a clinical trial suggest a new treatment for Covid-19 reduces the number of patients needing intensive care, according to the UK company that developed it.

    The treatment from Southampton-based biotech Synairgen uses a protein called interferon beta which the body produces when it gets a viral infection.

    The protein is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, in the hope that it will stimulate an immune respon...
  • Surgeons' response to COVID ‐19: modified workflow to adapt to the new normal

    28 Jul, 2020
    British Journal of Surgery publishes an article talking about how surgeons adapt to new normal.
    An optimized workflow is mandatory to restore surgical care to the population in the ‘new‐normal’ of COVID‐19 pandemic1-3. Our hospital was the largest tertiary centre in Beijing that continued to provide full‐ranged surgical care from January 26 through April 29. We have received 99 809 surgical outpatients and 4376 emergencies, and 5378 surgeries have been performed. We herein introduce our mo...
  • WHO Director-General's opening remarks at the media briefing on COVID-19 - 23 July 2020

    26 Jul, 2020
    WHO Director-General's opening remarks at the media briefing on COVID-19 - 23 July 2020
    Good morning, good afternoon and good evening.

    More than 15 million cases of COVID-19 have now been reported to WHO, and almost 620 thousand deaths.

    Although all countries have been affected, we continue to see intense transmission in a relatively small group of countries.

    Almost 10 million cases, or two-thirds of all cases globally, are from 10 countries, and almost half of all cas...
  • Achieving Technological Change Without Digital Fatigue

    21 Jul, 2020

    The COVID-19 pandemic has drastically accelerated the need for the advancement of healthcare’s digital transformation. The obligation to stay at home caused by the pandemic has sped up the transition from to face-to-face work to remote work through the use of digital technologies and web resources.

    Reliance on technology has negatively affected human attention, decision-making capacity, and emotional wellbeing - added to increased tension and lack of concentration. 31% of primary c...
  • Dexamethasone in Hospitalized Patients with Covid-19 | NEJM

    19 Jul, 2020


    An study of the RECOVERY Group bring good news about the use of Dexamethasone in COVID-19 patients. 

    Background

    Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.

    Methods

    In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we ra...
  • Dexamethasone in Hospitalized Patients with Covid-19 | NEJM

    19 Jul, 2020


    An study of the RECOVERY Group bring good news about the use of Dexamethasone in COVID-19 patients. 

    Background

    Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.

    Methods

    In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we ra...
  • Dexamethasone in Hospitalized Patients with Covid-19 | NEJM

    19 Jul, 2020


    An study of the RECOVERY Group bring good news about the use of Dexamethasone in COVID-19 patients. 

    Background

    Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.

    Methods

    In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we ra...